Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Computer Simulation and Knotted Chain Technology Yield Virtual Synthetic Proteins

By BiotechDaily International staff writers
Posted on 28 Feb 2013
Print article
Image: The self-knotted structure of the bionic protein (Copyright: Ivan Coluzza).
Image: The self-knotted structure of the bionic protein (Copyright: Ivan Coluzza).
Accessing a powerful computer complex, a team of Austrian physicists has developed virtual synthetic proteins as the first step to the in vitro synthesis of fully active "bionic proteins."

Physicists at the University of Vienna (Austria) together with investigators at the University of Natural Resources and Life Sciences (Vienna, Austria) exploited the computing power of The Vienna Scientific Cluster (Austria)—a pool of high-performance computing resources that covers the computing demands of four different Universities: the University of Vienna, Vienna University of Technology, the University of Natural Resources and Applied Life Science, and the Graz University of Technology—to develop a virtual mechanism for the construction of proteins from colloidal particles.

The "knotted chain" methodology, which was fully described in the February 11, 2013, issue of the journal Physical Review Letters, was used to construct self-assembling chains of simple particles, with final structures fully controlled by the sequence of particles along the chain. The individual particles forming the chain were colloids decorated with mutually interacting patches, which can be manufactured in the laboratory with current technology.

The methodology was applied to the design of sequences folding into self-knotting chains, in which the end monomers were by construction always close to each other in space. The knotted structure could then be externally locked simply by controlling the interaction between the end monomers, paving the way to applications in the design and synthesis of active materials and novel carriers for drugs delivery.

"Imitating these astonishing bio-mechanical properties of proteins and transferring them to a fully artificial system is our long term objective,” said first author Dr. Ivan Coluzza, research in the physics department at the University of Vienna.

Related Links:

University of Vienna
University of Natural Resources and Life Sciences
The Vienna Scientific Cluster



Print article

Channels

Genomics/Proteomics

view channel
Image: An artistic rendering of the Zika virus structure (Photo courtesy of Dr. Guntur Fibriansah, Duke-NUS Medical School).

High Resolution Structure of Zika virus Expected to Aid Vaccine Development

A team of molecular virologists used advanced cryo-electron microscopy techniques to establish a high-resolution structure for the Zika virus, a formerly neglected pathogen that has recently been associated... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.